Hepatocellular carcinoma (HCC) accounts for up to 90% of all primary hepatic malignancies and is the fifth most common malignancy and fourth leading cause of cancer-related death worldwide. 1,2 Treatment choices for patients with HCC are affected by the tumor stage, degree of liver dysfunction, and patient comorbidities.Liver transplantation (LT), liver resection (LR), and radiofrequency ablation are common curative treatment options, although LT is considered the best treatment strategy, as it removes the tumor and cures the underlying liver disease. 3,4 However, because of the shortage of available donor grafts leading to dropout or waiting-time mortality, LR is considered a reasonable first-line locoregional treatment modality in selected transplantation-eligible patients. Unfortunately,

No abstract